Onyx Healthcare Inc. (TPEX: 6569)
168.00
-5.50 (-3.17%)
Sep 10, 2024, 1:30 PM CST
Onyx Healthcare Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 1,382 | 1,493 | 1,600 | 1,202 | 1,347 | 1,483 | Upgrade
|
Revenue Growth (YoY) | -8.46% | -6.71% | 33.16% | -10.80% | -9.15% | 4.09% | Upgrade
|
Cost of Revenue | 853.78 | 936.72 | 1,128 | 838.03 | 883.3 | 940.3 | Upgrade
|
Gross Profit | 527.94 | 556.14 | 472.31 | 363.73 | 464.01 | 542.64 | Upgrade
|
Selling, General & Admin | 261.38 | 258.98 | 241.59 | 208.96 | 232.16 | 225.62 | Upgrade
|
Research & Development | 94.9 | 79.36 | 86.67 | 79.35 | 68.64 | 68.97 | Upgrade
|
Operating Expenses | 356.67 | 338.02 | 326.91 | 289.22 | 303.35 | 306.02 | Upgrade
|
Operating Income | 171.27 | 218.12 | 145.39 | 74.51 | 160.66 | 236.63 | Upgrade
|
Interest Expense | -3.84 | -3.68 | -3.56 | -2.63 | -0.48 | -1.26 | Upgrade
|
Interest & Investment Income | 8.08 | 3.39 | 4.69 | 6.36 | 2.29 | 2.18 | Upgrade
|
Earnings From Equity Investments | 65.7 | 62.87 | 62.94 | 50.19 | 33.9 | 18.93 | Upgrade
|
Currency Exchange Gain (Loss) | 2.31 | -7.42 | 19.28 | -6.02 | -12.29 | -4.88 | Upgrade
|
Other Non Operating Income (Expenses) | 8.18 | 19.85 | 25.41 | 18.57 | 14.67 | 2.87 | Upgrade
|
EBT Excluding Unusual Items | 251.68 | 293.14 | 254.14 | 140.98 | 198.76 | 254.46 | Upgrade
|
Gain (Loss) on Sale of Investments | 11.07 | 11.86 | -12.45 | -0.87 | 3.86 | 35.45 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | 0.25 | - | - | - | Upgrade
|
Other Unusual Items | -0.01 | 0.01 | 0.09 | -0.01 | - | - | Upgrade
|
Pretax Income | 262.75 | 305 | 242.03 | 140.11 | 202.61 | 289.91 | Upgrade
|
Income Tax Expense | 42.64 | 49.83 | 38.9 | 13.6 | 37.71 | 54.38 | Upgrade
|
Earnings From Continuing Operations | 220.11 | 255.17 | 203.14 | 126.51 | 164.91 | 235.53 | Upgrade
|
Minority Interest in Earnings | 0.79 | 0.09 | -0.18 | 1.04 | 2.17 | 3.85 | Upgrade
|
Net Income | 220.89 | 255.26 | 202.96 | 127.55 | 167.08 | 239.38 | Upgrade
|
Net Income to Common | 220.89 | 255.26 | 202.96 | 127.55 | 167.08 | 239.38 | Upgrade
|
Net Income Growth | -12.63% | 25.77% | 59.12% | -23.66% | -30.20% | 22.82% | Upgrade
|
Shares Outstanding (Basic) | 38 | 38 | 37 | 35 | 35 | 35 | Upgrade
|
Shares Outstanding (Diluted) | 39 | 39 | 38 | 35 | 35 | 35 | Upgrade
|
Shares Change (YoY) | 1.00% | 2.83% | 7.68% | -0.14% | 0.11% | -0.12% | Upgrade
|
EPS (Basic) | 5.74 | 6.66 | 5.43 | 3.67 | 4.80 | 6.88 | Upgrade
|
EPS (Diluted) | 5.68 | 6.60 | 5.39 | 3.65 | 4.77 | 6.85 | Upgrade
|
EPS Growth | -13.42% | 22.42% | 47.62% | -23.50% | -30.27% | 22.87% | Upgrade
|
Free Cash Flow | 336.97 | 282.91 | 149.84 | -277.64 | 179.82 | 367.64 | Upgrade
|
Free Cash Flow Per Share | 8.66 | 7.31 | 3.98 | -7.95 | 5.14 | 10.52 | Upgrade
|
Dividend Per Share | 4.348 | 4.348 | 4.348 | 3.479 | 4.348 | 3.795 | Upgrade
|
Dividend Growth | 0% | 0% | 25.00% | -20.00% | 14.58% | 1.54% | Upgrade
|
Gross Margin | 38.21% | 37.25% | 29.51% | 30.27% | 34.44% | 36.59% | Upgrade
|
Operating Margin | 12.40% | 14.61% | 9.09% | 6.20% | 11.92% | 15.96% | Upgrade
|
Profit Margin | 15.99% | 17.10% | 12.68% | 10.61% | 12.40% | 16.14% | Upgrade
|
Free Cash Flow Margin | 24.39% | 18.95% | 9.36% | -23.10% | 13.35% | 24.79% | Upgrade
|
EBITDA | 189.71 | 235.93 | 163.63 | 90.84 | 174.4 | 251.31 | Upgrade
|
EBITDA Margin | 13.73% | 15.80% | 10.23% | 7.56% | 12.94% | 16.95% | Upgrade
|
D&A For EBITDA | 18.44 | 17.81 | 18.24 | 16.33 | 13.74 | 14.68 | Upgrade
|
EBIT | 171.27 | 218.12 | 145.39 | 74.51 | 160.66 | 236.63 | Upgrade
|
EBIT Margin | 12.40% | 14.61% | 9.09% | 6.20% | 11.92% | 15.96% | Upgrade
|
Effective Tax Rate | 16.23% | 16.34% | 16.07% | 9.71% | 18.61% | 18.76% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.